View Future GrowthRenascience 과거 순이익 실적현재 이 회사의 최신 실적 보고서를 처리하고 있습니다과거 기준 점검 0/6Renascience은 연평균 25.4%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 6%의 비율로 증가했습니다. 매출은 연평균 8.3%의 비율로 감소했습니다.핵심 정보25.42%순이익 성장률27.25%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률3.41%매출 성장률-8.28%자기자본이익률-10.72%순이익률-242.06%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥5.25 loss per share (vs JP¥17.78 profit in 3Q 2025)Third quarter 2026 results: JP¥5.25 loss per share (down from JP¥17.78 profit in 3Q 2025). Net loss: JP¥67.0m (down 130% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.공시 • Nov 29Renascience Inc. to Report Q3, 2026 Results on Feb 13, 2026Renascience Inc. announced that they will report Q3, 2026 results on Feb 13, 2026Reported Earnings • Nov 15Second quarter 2026 earnings released: JP¥6.69 loss per share (vs JP¥4.41 loss in 2Q 2025)Second quarter 2026 results: JP¥6.69 loss per share (further deteriorated from JP¥4.41 loss in 2Q 2025). Net loss: JP¥85.0m (loss widened 52% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.공시 • Sep 01Renascience Inc. to Report Q2, 2026 Results on Nov 12, 2025Renascience Inc. announced that they will report Q2, 2026 results on Nov 12, 2025Reported Earnings • Aug 15First quarter 2026 earnings released: JP¥5.19 loss per share (vs JP¥1.26 loss in 1Q 2025)First quarter 2026 results: JP¥5.19 loss per share (further deteriorated from JP¥1.26 loss in 1Q 2025). Revenue: JP¥10.0m (down 75% from 1Q 2025). Net loss: JP¥66.0m (loss widened 313% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jun 30Full year 2025 earnings released: EPS: JP¥8.89 (vs JP¥20.30 loss in FY 2024)Full year 2025 results: EPS: JP¥8.89 (up from JP¥20.30 loss in FY 2024). Revenue: JP¥132.0m (down 32% from FY 2024). Net income: JP¥113.0m (up JP¥371.0m from FY 2024). Profit margin: 86% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.모든 업데이트 보기Recent updates공시 • May 13Renascience Inc., Annual General Meeting, Jun 25, 2026Renascience Inc., Annual General Meeting, Jun 25, 2026.New Risk • May 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.4b (US$98.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10.0% average weekly change). Revenue is less than US$1m (JP¥107m revenue, or US$679k). Minor Risk Market cap is less than US$100m (JP¥15.4b market cap, or US$98.0m).공시 • Mar 05Renascience Inc. announced that it has received ¥459.972744 million in funding from CVI Investments, Inc.On March 5, 2026, Renascience Inc closed the transaction. Stock acquisition right exercise till September 5, 2029.Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥5.25 loss per share (vs JP¥17.78 profit in 3Q 2025)Third quarter 2026 results: JP¥5.25 loss per share (down from JP¥17.78 profit in 3Q 2025). Net loss: JP¥67.0m (down 130% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.공시 • Nov 29Renascience Inc. to Report Q3, 2026 Results on Feb 13, 2026Renascience Inc. announced that they will report Q3, 2026 results on Feb 13, 2026Reported Earnings • Nov 15Second quarter 2026 earnings released: JP¥6.69 loss per share (vs JP¥4.41 loss in 2Q 2025)Second quarter 2026 results: JP¥6.69 loss per share (further deteriorated from JP¥4.41 loss in 2Q 2025). Net loss: JP¥85.0m (loss widened 52% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.공시 • Sep 01Renascience Inc. to Report Q2, 2026 Results on Nov 12, 2025Renascience Inc. announced that they will report Q2, 2026 results on Nov 12, 2025Reported Earnings • Aug 15First quarter 2026 earnings released: JP¥5.19 loss per share (vs JP¥1.26 loss in 1Q 2025)First quarter 2026 results: JP¥5.19 loss per share (further deteriorated from JP¥1.26 loss in 1Q 2025). Revenue: JP¥10.0m (down 75% from 1Q 2025). Net loss: JP¥66.0m (loss widened 313% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Jul 21High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman Toshio Miyata is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Jun 30Full year 2025 earnings released: EPS: JP¥8.89 (vs JP¥20.30 loss in FY 2024)Full year 2025 results: EPS: JP¥8.89 (up from JP¥20.30 loss in FY 2024). Revenue: JP¥132.0m (down 32% from FY 2024). Net income: JP¥113.0m (up JP¥371.0m from FY 2024). Profit margin: 86% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jun 03Renascience Inc. to Report Q1, 2026 Results on Aug 13, 2025Renascience Inc. announced that they will report Q1, 2026 results on Aug 13, 2025공시 • May 14Renascience Inc., Annual General Meeting, Jun 26, 2025Renascience Inc., Annual General Meeting, Jun 26, 2025.공시 • Mar 01Renascience Inc. to Report Fiscal Year 2025 Results on May 14, 2025Renascience Inc. announced that they will report fiscal year 2025 results on May 14, 2025New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (JP¥129m revenue, or US$815k). Minor Risks Share price has been volatile over the past 3 months (5.0% average weekly change). Market cap is less than US$100m (JP¥3.84b market cap, or US$24.2m).분석 기사 • Jan 01Is Renascience (TSE:4889) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...공시 • Dec 03Renascience Inc. to Report Q3, 2025 Results on Feb 13, 2025Renascience Inc. announced that they will report Q3, 2025 results on Feb 13, 2025공시 • Aug 28Renascience Inc. to Report Q2, 2025 Results on Nov 14, 2024Renascience Inc. announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 13First quarter 2025 earnings released: JP¥1.26 loss per share (vs JP¥0.16 profit in 1Q 2024)First quarter 2025 results: JP¥1.26 loss per share (down from JP¥0.16 profit in 1Q 2024). Net loss: JP¥16.0m (down JP¥18.0m from profit in 1Q 2024).New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (JP¥194m revenue, or US$1.2m). Market cap is less than US$100m (JP¥4.51b market cap, or US$28.8m).Board Change • Jul 05High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Outside Director Yasunori Nishiyama is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Jun 10Renascience Inc. to Report Q1, 2025 Results on Aug 08, 2024Renascience Inc. announced that they will report Q1, 2025 results on Aug 08, 2024Reported Earnings • May 11Full year 2024 earnings released: JP¥20.30 loss per share (vs JP¥26.35 loss in FY 2023)Full year 2024 results: JP¥20.30 loss per share (improved from JP¥26.35 loss in FY 2023). Revenue: JP¥194.0m (up 94% from FY 2023). Net loss: JP¥258.0m (loss narrowed 23% from FY 2023).공시 • May 11Renascience Inc., Annual General Meeting, Jun 27, 2024Renascience Inc., Annual General Meeting, Jun 27, 2024.분석 기사 • Apr 05Is Renascience (TSE:4889) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...공시 • Mar 02Renascience Inc. to Report Fiscal Year 2024 Results on May 09, 2024Renascience Inc. announced that they will report fiscal year 2024 results on May 09, 2024공시 • Nov 29Renascience Inc. to Report Q3, 2024 Results on Feb 08, 2024Renascience Inc. announced that they will report Q3, 2024 results on Feb 08, 2024공시 • Aug 30Renascience Inc. to Report Q2, 2024 Results on Nov 09, 2023Renascience Inc. announced that they will report Q2, 2024 results on Nov 09, 2023Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥0.16 (vs JP¥4.96 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥0.16 (up from JP¥4.96 loss in 1Q 2023). Revenue: JP¥93.0m (up 365% from 1Q 2023). Net income: JP¥2.00m (up JP¥65.0m from 1Q 2023). Profit margin: 2.2% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.공시 • Jun 02Renascience Inc. to Report Q1, 2024 Results on Aug 10, 2023Renascience Inc. announced that they will report Q1, 2024 results on Aug 10, 2023공시 • May 13Renascience Inc., Annual General Meeting, Jun 29, 2023Renascience Inc., Annual General Meeting, Jun 29, 2023.Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥5.74 loss per share (vs JP¥7.09 loss in 3Q 2022)Third quarter 2023 results: JP¥5.74 loss per share (improved from JP¥7.09 loss in 3Q 2022). Net loss: JP¥73.0m (loss narrowed 19% from 3Q 2022).공시 • Nov 27Renascience Inc. to Report Q3, 2023 Results on Feb 09, 2023Renascience Inc. announced that they will report Q3, 2023 results on Feb 09, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: JP¥7.08 loss per share (vs JP¥7.09 loss in 2Q 2022)Second quarter 2023 results: JP¥7.08 loss per share (improved from JP¥7.09 loss in 2Q 2022). Net loss: JP¥90.0m (flat on 2Q 2022).Reported Earnings • Nov 13Second quarter 2023 earnings released: JP¥7.08 loss per share (vs JP¥7.09 loss in 2Q 2022)Second quarter 2023 results: JP¥7.08 loss per share (improved from JP¥7.09 loss in 2Q 2022). Net loss: JP¥90.0m (flat on 2Q 2022).공시 • Aug 28Renascience Inc. to Report Q2, 2023 Results on Nov 10, 2022Renascience Inc. announced that they will report Q2, 2023 results on Nov 10, 2022Reported Earnings • Aug 13First quarter 2023 earnings releasedFirst quarter 2023 results: JP¥4.96 loss per share. Net loss: JP¥63.0m (flat on 1Q 2022).공시 • Jun 25Renascience Inc. to Report Q1, 2023 Results on Aug 10, 2022Renascience Inc. announced that they will report Q1, 2023 results on Aug 10, 2022공시 • May 14Renascience Inc., Annual General Meeting, Jun 29, 2022Renascience Inc., Annual General Meeting, Jun 29, 2022.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Apr 08Renascience Inc. to Report Fiscal Year 2022 Results on May 12, 2022Renascience Inc. announced that they will report fiscal year 2022 results on May 12, 2022공시 • Sep 25Renascience Inc. has completed an IPO in the amount of ¥1.977438 billion.Renascience Inc. has completed an IPO in the amount of ¥1.977438 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,951,400 Price\Range: ¥670 Discount Per Security: ¥53.6 Transaction Features: Sponsor Backed Offering매출 및 비용 세부 내역Renascience가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TSE:4889 매출, 비용 및 순이익 (JPY Millions)날짜매출순이익일반관리비연구개발비31 Dec 25107-25924813230 Sep 25873421013230 Jun 251026319413231 Mar 2513211315913231 Dec 241391185423630 Sep 24129-23512423630 Jun 24141-27615123631 Mar 24194-25816723631 Dec 23190-33124523530 Sep 23200-27720123530 Jun 23173-27019323531 Mar 23100-33518523531 Dec 22103-3162508230 Sep 22128-2882458230 Jun 22128-2852188231 Mar 22139-2541938231 Mar 21209-100265031 Mar 2072-1842350양질의 수익: 4889 은(는) 현재 수익성이 없습니다.이익 마진 증가: 4889는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 4889는 수익성이 없지만 지난 5년 동안 연평균 25.4%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 4889의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 4889은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(7.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 4889는 현재 수익성이 없으므로 자본 수익률이 음수(-10.72%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/15 00:03종가2026/05/15 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Renascience Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥5.25 loss per share (vs JP¥17.78 profit in 3Q 2025)Third quarter 2026 results: JP¥5.25 loss per share (down from JP¥17.78 profit in 3Q 2025). Net loss: JP¥67.0m (down 130% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Nov 29Renascience Inc. to Report Q3, 2026 Results on Feb 13, 2026Renascience Inc. announced that they will report Q3, 2026 results on Feb 13, 2026
Reported Earnings • Nov 15Second quarter 2026 earnings released: JP¥6.69 loss per share (vs JP¥4.41 loss in 2Q 2025)Second quarter 2026 results: JP¥6.69 loss per share (further deteriorated from JP¥4.41 loss in 2Q 2025). Net loss: JP¥85.0m (loss widened 52% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Sep 01Renascience Inc. to Report Q2, 2026 Results on Nov 12, 2025Renascience Inc. announced that they will report Q2, 2026 results on Nov 12, 2025
Reported Earnings • Aug 15First quarter 2026 earnings released: JP¥5.19 loss per share (vs JP¥1.26 loss in 1Q 2025)First quarter 2026 results: JP¥5.19 loss per share (further deteriorated from JP¥1.26 loss in 1Q 2025). Revenue: JP¥10.0m (down 75% from 1Q 2025). Net loss: JP¥66.0m (loss widened 313% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jun 30Full year 2025 earnings released: EPS: JP¥8.89 (vs JP¥20.30 loss in FY 2024)Full year 2025 results: EPS: JP¥8.89 (up from JP¥20.30 loss in FY 2024). Revenue: JP¥132.0m (down 32% from FY 2024). Net income: JP¥113.0m (up JP¥371.0m from FY 2024). Profit margin: 86% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.
공시 • May 13Renascience Inc., Annual General Meeting, Jun 25, 2026Renascience Inc., Annual General Meeting, Jun 25, 2026.
New Risk • May 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.4b (US$98.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10.0% average weekly change). Revenue is less than US$1m (JP¥107m revenue, or US$679k). Minor Risk Market cap is less than US$100m (JP¥15.4b market cap, or US$98.0m).
공시 • Mar 05Renascience Inc. announced that it has received ¥459.972744 million in funding from CVI Investments, Inc.On March 5, 2026, Renascience Inc closed the transaction. Stock acquisition right exercise till September 5, 2029.
Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥5.25 loss per share (vs JP¥17.78 profit in 3Q 2025)Third quarter 2026 results: JP¥5.25 loss per share (down from JP¥17.78 profit in 3Q 2025). Net loss: JP¥67.0m (down 130% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Nov 29Renascience Inc. to Report Q3, 2026 Results on Feb 13, 2026Renascience Inc. announced that they will report Q3, 2026 results on Feb 13, 2026
Reported Earnings • Nov 15Second quarter 2026 earnings released: JP¥6.69 loss per share (vs JP¥4.41 loss in 2Q 2025)Second quarter 2026 results: JP¥6.69 loss per share (further deteriorated from JP¥4.41 loss in 2Q 2025). Net loss: JP¥85.0m (loss widened 52% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Sep 01Renascience Inc. to Report Q2, 2026 Results on Nov 12, 2025Renascience Inc. announced that they will report Q2, 2026 results on Nov 12, 2025
Reported Earnings • Aug 15First quarter 2026 earnings released: JP¥5.19 loss per share (vs JP¥1.26 loss in 1Q 2025)First quarter 2026 results: JP¥5.19 loss per share (further deteriorated from JP¥1.26 loss in 1Q 2025). Revenue: JP¥10.0m (down 75% from 1Q 2025). Net loss: JP¥66.0m (loss widened 313% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Jul 21High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman Toshio Miyata is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Jun 30Full year 2025 earnings released: EPS: JP¥8.89 (vs JP¥20.30 loss in FY 2024)Full year 2025 results: EPS: JP¥8.89 (up from JP¥20.30 loss in FY 2024). Revenue: JP¥132.0m (down 32% from FY 2024). Net income: JP¥113.0m (up JP¥371.0m from FY 2024). Profit margin: 86% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jun 03Renascience Inc. to Report Q1, 2026 Results on Aug 13, 2025Renascience Inc. announced that they will report Q1, 2026 results on Aug 13, 2025
공시 • May 14Renascience Inc., Annual General Meeting, Jun 26, 2025Renascience Inc., Annual General Meeting, Jun 26, 2025.
공시 • Mar 01Renascience Inc. to Report Fiscal Year 2025 Results on May 14, 2025Renascience Inc. announced that they will report fiscal year 2025 results on May 14, 2025
New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (JP¥129m revenue, or US$815k). Minor Risks Share price has been volatile over the past 3 months (5.0% average weekly change). Market cap is less than US$100m (JP¥3.84b market cap, or US$24.2m).
분석 기사 • Jan 01Is Renascience (TSE:4889) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
공시 • Dec 03Renascience Inc. to Report Q3, 2025 Results on Feb 13, 2025Renascience Inc. announced that they will report Q3, 2025 results on Feb 13, 2025
공시 • Aug 28Renascience Inc. to Report Q2, 2025 Results on Nov 14, 2024Renascience Inc. announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 13First quarter 2025 earnings released: JP¥1.26 loss per share (vs JP¥0.16 profit in 1Q 2024)First quarter 2025 results: JP¥1.26 loss per share (down from JP¥0.16 profit in 1Q 2024). Net loss: JP¥16.0m (down JP¥18.0m from profit in 1Q 2024).
New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (JP¥194m revenue, or US$1.2m). Market cap is less than US$100m (JP¥4.51b market cap, or US$28.8m).
Board Change • Jul 05High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Outside Director Yasunori Nishiyama is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Jun 10Renascience Inc. to Report Q1, 2025 Results on Aug 08, 2024Renascience Inc. announced that they will report Q1, 2025 results on Aug 08, 2024
Reported Earnings • May 11Full year 2024 earnings released: JP¥20.30 loss per share (vs JP¥26.35 loss in FY 2023)Full year 2024 results: JP¥20.30 loss per share (improved from JP¥26.35 loss in FY 2023). Revenue: JP¥194.0m (up 94% from FY 2023). Net loss: JP¥258.0m (loss narrowed 23% from FY 2023).
공시 • May 11Renascience Inc., Annual General Meeting, Jun 27, 2024Renascience Inc., Annual General Meeting, Jun 27, 2024.
분석 기사 • Apr 05Is Renascience (TSE:4889) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
공시 • Mar 02Renascience Inc. to Report Fiscal Year 2024 Results on May 09, 2024Renascience Inc. announced that they will report fiscal year 2024 results on May 09, 2024
공시 • Nov 29Renascience Inc. to Report Q3, 2024 Results on Feb 08, 2024Renascience Inc. announced that they will report Q3, 2024 results on Feb 08, 2024
공시 • Aug 30Renascience Inc. to Report Q2, 2024 Results on Nov 09, 2023Renascience Inc. announced that they will report Q2, 2024 results on Nov 09, 2023
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥0.16 (vs JP¥4.96 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥0.16 (up from JP¥4.96 loss in 1Q 2023). Revenue: JP¥93.0m (up 365% from 1Q 2023). Net income: JP¥2.00m (up JP¥65.0m from 1Q 2023). Profit margin: 2.2% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.
공시 • Jun 02Renascience Inc. to Report Q1, 2024 Results on Aug 10, 2023Renascience Inc. announced that they will report Q1, 2024 results on Aug 10, 2023
공시 • May 13Renascience Inc., Annual General Meeting, Jun 29, 2023Renascience Inc., Annual General Meeting, Jun 29, 2023.
Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥5.74 loss per share (vs JP¥7.09 loss in 3Q 2022)Third quarter 2023 results: JP¥5.74 loss per share (improved from JP¥7.09 loss in 3Q 2022). Net loss: JP¥73.0m (loss narrowed 19% from 3Q 2022).
공시 • Nov 27Renascience Inc. to Report Q3, 2023 Results on Feb 09, 2023Renascience Inc. announced that they will report Q3, 2023 results on Feb 09, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: JP¥7.08 loss per share (vs JP¥7.09 loss in 2Q 2022)Second quarter 2023 results: JP¥7.08 loss per share (improved from JP¥7.09 loss in 2Q 2022). Net loss: JP¥90.0m (flat on 2Q 2022).
Reported Earnings • Nov 13Second quarter 2023 earnings released: JP¥7.08 loss per share (vs JP¥7.09 loss in 2Q 2022)Second quarter 2023 results: JP¥7.08 loss per share (improved from JP¥7.09 loss in 2Q 2022). Net loss: JP¥90.0m (flat on 2Q 2022).
공시 • Aug 28Renascience Inc. to Report Q2, 2023 Results on Nov 10, 2022Renascience Inc. announced that they will report Q2, 2023 results on Nov 10, 2022
Reported Earnings • Aug 13First quarter 2023 earnings releasedFirst quarter 2023 results: JP¥4.96 loss per share. Net loss: JP¥63.0m (flat on 1Q 2022).
공시 • Jun 25Renascience Inc. to Report Q1, 2023 Results on Aug 10, 2022Renascience Inc. announced that they will report Q1, 2023 results on Aug 10, 2022
공시 • May 14Renascience Inc., Annual General Meeting, Jun 29, 2022Renascience Inc., Annual General Meeting, Jun 29, 2022.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Apr 08Renascience Inc. to Report Fiscal Year 2022 Results on May 12, 2022Renascience Inc. announced that they will report fiscal year 2022 results on May 12, 2022
공시 • Sep 25Renascience Inc. has completed an IPO in the amount of ¥1.977438 billion.Renascience Inc. has completed an IPO in the amount of ¥1.977438 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,951,400 Price\Range: ¥670 Discount Per Security: ¥53.6 Transaction Features: Sponsor Backed Offering